TWO Israeli businessmen with strong UK links have joined forces to deliver high-quality cannabis terpenes to European consumers.
CiiTech, a leading cannabis business, has partnered with Kanabo Research to launch terpene formulas for use with the latter’s VapePod.
In a press release the partners say they will use CiiTech’s ‘terpene formulas to meet the highest standards required for the UK market’.
These have been designed specifically for use with the VapePod, Kanabo’s patented device which was the first to be approved for medical use by the Israeli Ministry of Health.
Terpenes are essential plant oils that deliver distinctive flavors and smells and include the likes of linalool – also present in lavender – and pinene, in conifers.
They also confer therapeutic effects, with cannabis terpenes being used to promote sleep, fight inflammation and boost mood.
CiiTech was was founded by Clifton Flack, once of iCAN and the investment platform CannaTech.
The London-based company initiates in-house research and created Provocan which has been selected as best in class among UK CBD brands.
He said trust in CBD brands is ‘crucial’ and collaboration with partners such as Kanabo can help achieve that.
He added: “There’s a real growth in consumer understanding of the terpenes.
“We believe our proven formulas created with Kanabo for the VapePod device deliver an exceptional level of CBD innovation and efficacy not previously seen in the industry.”
Kanabo plans to list on the London Stock Exchange in what will be an effective reverse takeover with UK shell company Spinnaker Opportunities PLC.